Filtered By:
Therapy: Neoadjuvant Therapy
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 32 results found since Jan 2013.
Developments in targeted therapy & amp; immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review
CONCLUSIONS: This review encompasses the latest updates in targeted therapy and immunotherapy in lung cancer management and discusses the future direction in the field.PMID:37675321 | PMC:PMC10477626 | DOI:10.21037/atm-22-4444
Source: Cancer Control - September 7, 2023 Category: Cancer & Oncology Authors: Molly S C Li Kevin K S Mok Tony S K Mok Source Type: research
Carcinoma vulva: Ten years experience in a teaching institution of North India
CONCLUSION: Tumour stage, nodal positivity and nodal ECS were poor prognostic factors. Radical surgery-extensive groin node dissection causes significant morbidity; hence, studies evaluating the role of neoadjuvant treatment are needed so as to modify current treatment practices. HPV vaccination as a preventive measure and a thorough and extensive evaluation of patients with suspicious signs in vulvar disease is needed.PMID:37312782 | PMC:PMC10259558 | DOI:10.4103/jfmpc.jfmpc_1731_22
Source: Primary Care - June 14, 2023 Category: Primary Care Authors: Lajya Devi Goyal Balpreet Kaur Shivali Bhalla Pardeep Garg Source Type: research
An update on Merkel cell carcinoma
Biochim Biophys Acta Rev Cancer. 2023 Mar 11:188880. doi: 10.1016/j.bbcan.2023.188880. Online ahead of print.ABSTRACTMerkel cell carcinoma (MCC) is a rare cancer of the skin characterized by a neuroendocrine phenotype and an aggressive clinical behavior. It frequently originates in sun-exposed body areas, and its incidence has steadily increased in the last three decades. Merkel cell polyomavirus (MCPyV) and ultraviolet (UV) radiation exposure are the main causative agents of MCC, and distinct molecular features have been documented in virus-positive and virus-negative malignancies. Surgery remains the cornerstone of treat...
Source: Biochimica et Biophysica Acta - March 13, 2023 Category: Biochemistry Authors: Maria Chiara Sergi Eleonora Lauricella Camillo Porta Marco Tucci Mauro Cives Source Type: research
The role of PRAME and NY-ESO-1 as potential therapeutic and prognostic biomarkers in triple-negative breast carcinomas
This study aims to analyze PRAME and NY-ESO-1 expression in TNBCs and their correlation with clinical outcomes. This is a retrospective cohort study of TNBC patients who have undergone neoadjuvant chemotherapy. PRAME and NY-ESO-1 expression were assessed on pre-therapy biopsies as H-scores (percentage x intensity) with final H scores of 2-3 considered as positive. Association between expression and pathologic complete response (pCR), metastasis, and residual cancer burden (RCB) were assessed via logistic regression. Cox proportional hazards models were used to assess the association with progression-free survival. P-values...
Source: Pathology, Research and Practice - January 5, 2023 Category: Pathology Authors: Sharlene Helene C See Steven H Smith Brian S Finkelman Carissa LaBoy Jorge E Novo Kalliopi P Siziopikou Luis Z Blanco Source Type: research
Safety and Efficacy of MEDI0457 Plus Durvalumab in Patients With Human Papillomavirus-associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
CONCLUSIONS: MEDI0457 plus durvalumab was well tolerated. While the primary efficacy endpoint was not reached, clinical benefit was encouraging.PMID:36455147 | DOI:10.1158/1078-0432.CCR-22-1987
Source: Clinical Cancer Research - December 1, 2022 Category: Cancer & Oncology Authors: Charu Aggarwal Nabil F Saba Alain Algazi Ammar Sukari Tanguy Y Seiwert Missak Haigentz Mercedes Porosnicu Marcelo Bonomi Jean Boyer Mark T Esser Lily I Cheng Sonia Agrawal Emily C Jennings Nicholas M Durham Karl Fraser Delphine Lissa Maozhen Gong Natalia Source Type: research
Immunotherapy in head and neck squamous cell carcinoma: An updated review
Cancer Treat Res Commun. 2022 Oct 14;33:100649. doi: 10.1016/j.ctarc.2022.100649. Online ahead of print.ABSTRACTSquamous cell cancer of the head and neck (HNSCC) is the sixth most common cancer and is associated with significant morbidity and mortality. The tumor microenvironment for HNSCC is a complex interplay of immune cells, stromal cells, and cytokines amongst others. Immunotherapy acts as an effective antineoplastic agent by influencing this complex environment and includes immune checkpoint inhibitors (ICI). ICI have been approved in the frontline setting for recurrent and metastatic (R/M) HNSCC as well as platinum-...
Source: Cell Research - October 24, 2022 Category: Cytology Authors: K Parmar A Mohamed E Vaish R Thawani J Cetnar K Z Thein Source Type: research
A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an < em > in situ < /em > vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial
Future Oncol. 2022 Jun 15. doi: 10.2217/fon-2022-0380. Online ahead of print.ABSTRACTThe utilization of neoadjuvant immune checkpoint inhibitor therapy, specifically anti-PD-1/L1 agents, prior to radical cystectomy is an emerging paradigm in muscle-invasive bladder cancer (MIBC). In situ vaccination represents a strategy to manipulate the tumor in order to augment the immune response toward improved local and distant cancer control. The authors describe the study rationale, design and objectives for RAD VACCINE MIBC, a single-arm, single-institution, phase II trial evaluating the efficacy and safety of combination neoadjuv...
Source: Cancer Control - June 15, 2022 Category: Cancer & Oncology Authors: Raj Satkunasivam Kelvin Lim Bin S Teh Jonathan Guzman Jun Zhang Andrew Farach Shu-Hsia Chen Christopher Jd Wallis Eleni Efstathiou Nestor F Esnaola Guru P Sonpavde Source Type: research
Improved T cell immunity following neoadjuvant chemotherapy in ovarian cancer
CONCLUSIONS: NACT may alleviate tumor-associated immunosuppression by reducing tumor burden and may enhance antigen processing and presentation. These findings have implications for the successful combinatorial applications of immune checkpoint blockade and therapeutic vaccine approaches in EOC.PMID:35443043 | DOI:10.1158/1078-0432.CCR-21-2834
Source: Clinical Cancer Research - April 20, 2022 Category: Cancer & Oncology Authors: Min Liu Nabihah Tayob Livius Penter MacLean Sellars Anna Tarren Vipheaviny Chea Isabel Carulli Teddy Huang Shuqiang Li Su-Chun Cheng Phuong Le Laura Frackiewicz Julia Fasse Courtney Qi Joyce F Liu Elizabeth H Stover Jennifer Curtis Kenneth J Livak Donna N Source Type: research
Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy
Cancer Immunol Immunother. 2022 Apr 16. doi: 10.1007/s00262-022-03194-5. Online ahead of print.ABSTRACTThe aim of this study was to determine the efficacy and the biomarkers of the CHP-NY-ESO-1 vaccine complexed with full-length NY-ESO-1 protein and a cholesteryl pullulan (CHP) in patients with esophageal squamous cell carcinoma (ESCC) after surgery. We conducted a randomized phase II trial. Fifty-four patients with NY-ESO-1-expressing ESCC who underwent radical surgery following cisplatin/5-fluorouracil-based neoadjuvant chemotherapy were assigned to receive either CHP-NY-ESO-1 vaccination or observation as control. Six d...
Source: Cancer Control - April 16, 2022 Category: Cancer & Oncology Authors: Yasuhiro Nagata Shinichi Kageyama Takeshi Ishikawa Satoshi Kokura Tetsuya Okayama Tetsuya Abe Masahiko Murakami Koji Otsuka Tomotake Ariyoshi Takashi Kojima Ken Taniguchi Shinichiro Kobayashi Hideaki Shimada Satoshi Yajima Takashi Suzuki Satoshi Hirano Ta Source Type: research
Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer
Urol Oncol. 2020 Oct 23:S1078-1439(20)30477-4. doi: 10.1016/j.urolonc.2020.10.004. Online ahead of print.ABSTRACTNon-muscle-invasive bladder cancer is one of the most common malignancies. Patients with intermediate-risk or high-risk disease can be treated with intravesical Bacillus Calmette-Guerin, a vaccine against tuberculosis. However, many of these patients will experience tumor recurrence, despite appropriate treatment. 1 The standard of care in these patients is radical cystectomy (RC) with urinary diversion. 2 Patients diagnosed with muscle-invasive bladder cancer (MIBC) have traditionally faced 2 main treatment opt...
Source: Urologic Oncology - November 10, 2021 Category: Urology & Nephrology Authors: Rosa Nadal Andrea B Apolo Daniel M Girardi Noah M Hahn Joaquim Bellmunt Source Type: research
